KOL | Werner MD HackeDepartment of Neurology, Ruprecht-Karl-University Heidelberg, Heidelberg, Germany | RUPRECHT KARLS UNIV HEIDELBERG, Heidelberg, Germany | Department of Neurology, University ... |
KOL Resume for Werner MD Hacke
| Year | |
|---|---|
| 2022 | Department of Neurology, Ruprecht-Karl-University Heidelberg, Heidelberg, Germany |
| 2021 | Department of Neurology, University of Heidelberg, Germany (W.H.). Neurology, University of Heidelberg, Heidelberg, Germany RUPRECHT KARLS UNIV HEIDELBERG, Heidelberg |
| 2020 | The Department of Neurology, University of Heidelberg, Germany (W.H.). University of Heidelberg, Department of Neurology, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany |
| 2019 | Neurology, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany |
| 2018 | Ruprecht-Karls-University, Heidelberg, Germany |
| 2017 | From the Department of Neurology, University of Heidelberg, Heidelberg, Germany. 4, Department of Neurology, Heidelberg University, Heidelberg, Germany Neurologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland |
| 2016 | University of Heidelberg, Heidelberg, Germany. Department of Neurology, Universitätsklinikum Heidelberg, Heidelberg, Germany |
| 2015 | Neurologische Klinik, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland Department of Neurology, University Hospital Heidelberg, 69120 Heidelberg, Germany |
| 2014 | Department of Neurology Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA Neurologische Klinik, Universität Heidelberg, INF 400, 69120, Heidelberg, Deutschland |
| 2013 | From the Divisions of Critical Care and Cardiology, University of Alberta, Edmonton, Alberta, Canada (S.v.D.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (A.S.H., M.R.P., R.C.B., K.W.M.); Department of Cardiology and Angiology, Hospital of the University of Münster, Münster, Germany (G.B.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Mount Sinai Medical Center, New York, NY (J.L.H.); Royal Perth Hospital, Perth, WA, Australia (G.J.H.); Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); Bayer HealthCare Pharmaceuticals, Montville, NJ (S.D.B.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh, Scotland, United Kingdom (K.A.A.F.). Department of Neurology, University of Heidelberg, INF 400, 69120, Heidelberg, Germany ROCKET AF Steering Committee & Investigators, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA |
Werner MD Hacke: Influence Statistics
| Concept | World rank |
|---|---|
| fasttrack intubation | #1 |
| professional guideline | #1 |
| angiographic workflow treatment | #1 |
| dwiflairmismatch ecass4 trial | #1 |
| hacke | #1 |
| catastrophic outcome rtpa | #1 |
| 42 minutes | #1 |
| thrombolysis stroke subtype | #1 |
| 2016methodswe | #1 |
| outcome dichotomised analysis | #1 |
| negative stroke trial | #1 |
| cbf physiologic point | #1 |
| 3 months mortality | #1 |
| dwi delay | #1 |
| occlusion thrombolytic therapy | #1 |
| selected stroke | #1 |
| 110–418surgery | #1 |
| ivt discharge | #1 |
| treatment strategies icp | #1 |
| ischemic attack germany | #1 |
| intraarterial thrombectomy tpa | #1 |
| sss icp | #1 |
| eusi behalf | #1 |
| fatal intracerebral hemorrhage | #1 |
| ventricles primary ivh | #1 |
| baseline nihss 271360 | #1 |
| simplex glucocorticoids | #1 |
| patients basilar occlusion | #1 |
| european countries proportion | #1 |
| acute basilar artery | #1 |
| csc psc | #1 |
| stroke centers phase | #1 |
| ctasi cta | #1 |
| therapy average | #1 |
| patients favourable outcomes | #1 |
| retrospective analysis implementation | #1 |
| ivt hospital | #1 |
| patients baep patterns | #1 |
| levels csc | #1 |
| 149 rate | #1 |
| recanalization 8 hours | #1 |
| nindss differences | #1 |
| intravenous rtpa treatment | #1 |
| preexisting disabilities age | #1 |
| cas north americans | #1 |
| intravenous rtpa onset | #1 |
| general therapy | #1 |
| acute occlusion mortality | #1 |
| tests baroreflex sensitivity | #1 |
| late hypothermia cbf | #1 |
Open the FULL List in Excel | |
Prominent publications by Werner MD Hacke
BACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).
METHODS: In ROCKET AF, patients with AF who were at increased risk of stroke were randomly assigned (1:1) in a ...
| Known for Previous Stroke | Warfarin Patients | Atrial Fibrillation | Transient Ischaemic Attack | Rocket Rivaroxaban |
BACKGROUND: Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). This prespecified secondary analysis compares outcomes in older and younger ...
| Known for Atrial Fibrillation | Direct Factor | Warfarin Rivaroxaban | Oral Aged Aged | Embolism Trial |
BACKGROUND: The prevalence of both atrial fibrillation (AF) and diabetes mellitus (DM) are rising, and these conditions often occur together. Also, DM is an independent risk factor for stroke in patients with AF. We aimed to examine the safety and efficacy of rivaroxaban vs warfarin in patients with nonvalvular AF and DM in a prespecified secondary analysis of the ROCKET AF trial.
METHODS: We stratified the ROCKET AF population by DM status, assessed associations with risk of outcomes by ...
| Known for Patients Dm | Atrial Fibrillation | Rivaroxaban Warfarin | Efficacy Safety | Direct Factor |
Importance: Optimal management of sedation and airway during thrombectomy for acute ischemic stroke is controversial due to lack of evidence from randomized trials.
Objective: To assess whether conscious sedation is superior to general anesthesia for early neurological improvement among patients receiving stroke thrombectomy.
Design, Setting, and Participants: SIESTA (Sedation vs Intubation for Endovascular Stroke Treatment), a single-center, randomized, parallel-group, open-label ...
| Known for Conscious Sedation | General Anesthesia | Ischemic Stroke | 24 Hours | 3 Months |
BACKGROUND: Previous studies have suggested that desmoteplase, a novel plasminogen activator, has clinical benefit when given 3-9 h after the onset of the symptoms of stroke in patients with presumptive tissue at risk that is identified by magnetic resonance perfusion imaging (PI) and diffusion-weighted imaging (DWI).
METHODS: In this randomised, placebo-controlled, double-blind, dose-ranging study, patients with acute ischaemic stroke and tissue at risk seen on either MRI or CT imaging ...
| Known for Acute Ischaemic Stroke | Intravenous Desmoteplase | Mri Perfusion | Weighted Imaging | Lesion Volume |
Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial
[ PUBLICATION ]
OBJECTIVES: This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial fibrillation (AF) treated with warfarin or rivaroxaban.
BACKGROUND: There are limited data on outcomes following cardioversion or catheter ablation in AF patients treated with factor Xa inhibitors.
METHODS: We compared the incidence of electrical cardioversion (ECV), pharmacologic cardioversion (PCV), or AF ablation and subsequent outcomes in patients in a post ...
| Known for Rivaroxaban Warfarin | Cardioversion Ablation | Atrial Fibrillation | Stroke Patients | Systemic Embolism |
BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.
METHODS: In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or ...
| Known for Atrial Fibrillation | Year Warfarin | Primary Point | Stroke Rivaroxaban | Fatal Bleeding |
BACKGROUND AND PURPOSE: Although stroke MRI has advantages over other diagnostic imaging modalities in acute stroke patients, most of these individuals are admitted to emergency units without MRI facilities. There is a need for an accurate diagnostic tool that rapidly and reliably detects hemorrhage, extent of ischemia, and vessel status and potentially estimates tissue at risk. We sought to determine the diagnostic accuracy of the combination of non-contrast-enhanced CT, CT angiography ...
| Known for 6 Hours | Acute Stroke | Angiography Source Images | Cta Dwi | Collateral Status |
Monitoring Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis for Acute Ischemic Stroke With Diffusion and Perfusion MRI
[ PUBLICATION ]
BACKGROUND AND PURPOSE: Intravenous recombinant tissue plasminogen activator (rtPA) administration is an effective therapy for ischemic stroke when initiated within 3 hours and possibly up to 6 hours after symptom onset. To improve patient selection, a fast diagnostic tool that allows reliable diagnosis of hemorrhage and ischemia, vessel status, and tissue at risk at an early stage may be useful. We studied the feasibility of stroke MRI for the initial evaluation and follow-up monitoring ...
| Known for Stroke Mri | Plasminogen Activator | Recombinant Tissue | Dwi Pwi | Symptom Onset |
Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation
[ PUBLICATION ]
BACKGROUND: In Rivaroxaban Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), rivaroxaban was noninferior to warfarin for the prevention of stroke and systemic embolic events and significantly reduced intracranial bleeding in patients with nonvalvular atrial fibrillation. We explore the safety and efficacy of rivaroxaban in patients with heart failure (HF).
METHODS AND RESULTS: A ...
| Known for Patients Hf | Nonvalvular Atrial Fibrillation | Heart Failure | Rivaroxaban Warfarin | Efficacy Safety |
BACKGROUND: Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke.
METHODS: After exclusion of patients with a brain hemorrhage or major infarction, as detected on a computed tomographic scan, we randomly assigned ...
| Known for Acute Ischemic Stroke | Alteplase Placebo | Onset Symptoms | Efficacy Safety | Intracranial Hemorrhage |
OBJECTIVES: The purpose of this study was to understand the possible risk of discontinuation in the context of clinical care.
BACKGROUND: Rivaroxaban is noninferior to warfarin for preventing stroke in atrial fibrillation patients. Concerns exist regarding possible increased risk of stroke and non-central nervous system (CNS) thromboembolic events early after discontinuation of rivaroxaban.
METHODS: We undertook a post-hoc analysis of data from the ROCKET AF (Rivaroxaban Once-Daily, ...
| Known for Atrial Fibrillation | Direct Factor | Rivaroxaban Stroke | Embolism Trial | Warfarin Patients |
Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours
[ PUBLICATION ]
BACKGROUND AND PURPOSE: The goals of this study were to examine MRI baseline characteristics of patients with acute ischemic stroke (AIS) and to study the influence of intravenous tissue plasminogen activator (tPA) on MR parameters and functional outcome using a multicenter approach.
METHODS: In this open-label, nonrandomized study of AIS patients with suspected anterior circulation stroke, subjects received a multiparametric stroke MRI protocol (diffusion- and perfusion-weighted imaging ...
| Known for Functional Outcome | 6 Hours | Intravenous Thrombolysis | Acute Stroke | Mri Parameters |
OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks.
DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent ...
| Known for Atrial Fibrillation | Mortality Stroke | Bleeding Risk | Patients Anticoagulation | Cha2ds2 Vasc |
Key People For Atrial Fibrillation
Werner MD Hacke:Expert Impact
Concepts for whichWerner MD Hackehas direct influence:Atrial fibrillation, Ischemic stroke, Acute ischemic stroke, Thrombolytic therapy, Acute stroke, Stroke patients, Acute ischemic, Intravenous thrombolysis.
Werner MD Hacke:KOL impact
Concepts related to the work of other authors for whichfor which Werner MD Hacke has influence:Atrial fibrillation, Ischemic stroke, Mechanical thrombectomy, Oral anticoagulants, Intravenous thrombolysis, Endovascular treatment, Thrombolytic therapy.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |